Study of Formulation and Process Variables for Optimization of Piroxicam Nanosuspension Using 3 Factorial Design to Improve Solubility and In Vitro Bioavailability.

Piroxicam is a Biopharmaceutical Classification System (BCS) Class II drug having poor aqueous solubility and a short half-life. The rationale behind the present research was to develop a Piroxicam nanosuspension to enhance the solubility and thereby the in vitro bioavailability of the drug. Piroxicam nanosuspension (PRX NS) was prepared by an anti-solvent precipitation technique and optimized using a full-factorial design.

Lung delivery of nanoliposomal salbutamol sulfate dry powder inhalation for facilitated asthma therapy.

The motive behind present work was to discover a solution for overcoming the problems allied with a deprived oral bioavailability of salbutamol sulfate (SS) due to its first pass hepatic metabolism, shorter half-life, and systemic toxicity at high doses. Pulmonary delivery provides an alternative route of administration to avoid hepatic metabolism of SS, moreover facilitated diffusion and prolonged retention can be achieved by incorporation into liposomes. Liposomes were prepared by thin film hydration technique using 3 full factorial design and formulation was optimized based on the vesicle size and percent drug entrapment (PDE) of liposomes.